Schürmann, Dirk <br/><br/>
Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.  [electronic resource] 

 -  AIDS (London, England)  Jan 2006 
 - 138-40 p.  digital 
<br/><br/> Publication Type: Case Reports; Letter 
<br/><br/><label>ISSN: </label>0269-9370 
<br/><br/><label>Standard No.: </label>10.1097/01.aids.0000198080.32207.3c  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antiretroviral Therapy, Highly Active--methods<br/>Carbamates--therapeutic use<br/>Drug Resistance, Viral--genetics<br/>Drug Therapy, Combination<br/>Furans<br/>Genotype<br/>HIV Infections--drug therapy<br/>HIV Protease Inhibitors--therapeutic use<br/>Humans<br/>Male<br/>Mutation<br/>Organophosphates--therapeutic use<br/>Prodrugs--therapeutic use<br/>Sulfonamides--therapeutic use